Cambridge researchers develop robotic nerve devices for neurological conditions
Neurological disorders, such as epilepsy or chronic pain, affect over three billion people worldwide
Read More
Author: Jen Brogan
International phase 3 clinical trial for new melanoma treatment recruits first patients
The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Read More
Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
The inherited disorder is caused by genetic mutations that affects haemoglobin production
Read More
Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
Bacteroides fragilis in the gut improves immunity and immunotherapy treatment responses
Read More
Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
The progressive neurological condition affects more than six million people worldwide
Read More- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
